Diagnosed Heart Failure

VHVI Main Heart Registry
PI – McPherson
SC – Criswell / ALL

Energy Starvation Study
To employ PET and CMR to evaluate several determinants of myocardial “energy starvation” in patients with HF due to nonischemic dilated cardiomyopathies
PI – Kronenberg
SC – White/Nagy

ATMOSPHERE
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV)
PI – DiSalvo
SC - White/Nagy

Walk Study
A prospective, placebo-controlled, randomized, pilot study examining the effect of exercise in heart failure patients
PI – Geisberg
SC – Geisberg

Predicting Effects of HF in Breast CA
Predicting HF in patients with breast cancer by levels of early progenitor cells at baseline
PI – Sawyer/Geisberg
SC – White/Nagy

FOCUS
Randomized, controlled, phase II, double-blind trial of intramyocardial injection of autologous bone marrow mononuclear stem cells under electromechanical guidance for patients with chronic ischemic heart disease and left ventricular dysfunction
PI – Zhao
SC – Bowman/Francescon

TOPCAT
A multicenter, international, randomized, double-blind placebo-controlled trial of the aldosterone antagonist, spironolactone, in adults with heart failure and left ventricular ejection fraction of at least 45%
PI – Naftilan
SC – NagyWhite

Preventing Heart Failure

VHVI Main Heart Registry
PI – McPherson
SC – Criswell / ALL

Breast Cancer Patients being treated with Anthracyclines or Her2+

Patients being treated with Anthracyclines

If you have a patient who may qualify, please contact Study Coordinator (SC) Contact Numbers:
Sherry Bowman, RN  – 615.403.3039
Rachel Criswell, MS – 615.936.191
Judy Francescon, RN – 615.403.3880
Sarah Nagy, RN – 615.343.6238
Brenda White, RN  – 615.936.2458
PI/SC – Carrie Geisberg, MD  - 615.299.6610

If you have a patient who may qualify, please contact Study Coordinator (SC) Contact Numbers:
Sherry Bowman, RN  – 615.403.3039
Rachel Criswell, MS – 615.936.191
Judy Francescon, RN – 615.403.3880
Sarah Nagy, RN – 615.343.6238
Brenda White, RN  – 615.936.2458
PI/SC – Carrie Geisberg, MD  - 615.299.6610
Inplanted Device

ICD/CRT/PACEMAKER

Flow chart

PI – Whalen
SC/DT – Hale/White

SCORE-Registry
Medical product longevity and performance registry
PI – Rottman
SC/DT – Hale/Nagy

PACEMAKER Study
Modulation of QT Interval by Rapid Atrial Pacing in Patients with Dual Chamber Pacemakers
PI – Darbar
SC – Richardson
DT – Hale

Primary Prevention of SCD
No VT
No prior ICD

Provide
Randomized to specific settings to prevent or prolong time to first shock
PI – Whalen
SC/DT – Hale/White

No CAD/CHF
SSS only
QT Change with Rapid Pacing

If you have a patient who may qualify, please contact Study Coordinator (SC) Contact Numbers:
Rachel Criswell, MS – 615.936.7191
Leslie Hale (Device Tech) – 615.818.8011
Sarah Nagy, RN – 615.343.6238
Rachael Richardson, RN – 615.322.3173
Brenda White, RN – 615.936.2458
If you have a patient who may qualify, please contact Study Coordinator (SC) Contact Numbers:
Rachel Criswell, MS – 615.936.7191
Leslie Hale, Device Tech - 615.818.8011
Gayle Kucera, RN – 615.936.6069
Sarah Nagy, RN - 615.343.6238
Rachael Richardson, RN – 615.322.3173
Tonya Stubblefield, RN - 615.936.1984
Valerie Sullenger, RN – 615.343.7065
Brenda White, RN – 615.936.2458

Atrial Fibrillation (AF)

VHVI Main Heart Registry
PI – McPherson
SC – Criswell / ALL

Maze Procedure
Chronic AF

Paroxysmal AFib

No Amiodarone

Registry (Hybrid Procedures)

CABANA
Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation
PI – Darbar
SC – Nagy/White
DT - Hale

Need for Cardioversion

QT Variability Study
Assessing biomarkers of QT variability pre & post AF cardioversion
PI – Darbar
SC – Richardson
DT - Hale

Recurrent AF either treated or not documented Arrhythmia

Fish Oil Study
Randomized placebo controlled trial to see if Fish Oil decreases AF recurrence
PI – Stein
SC – Sullinger

Genetic AF Registry
To study genetics of AF
PI – Darbar
SC-Kucera/Stubblefield
**If you have a patient who may qualify, please contact**

**Study Coordinator (SC) Contact Numbers:**
Lynn Blair-Anton, RN – 615.484.3657
Sherry Bowman, RN – 615.403.3039
Michelle Clark, RN – 615.322.9349
Rachel Criswell, MS – 615.936.7191
Kim Crum, RN – 615.343.9071
Mary Gordon, RN – 615.936.8377
Judy Francescon, RN – 615.403.3880
Christa LaFontaine – 615.936.6991
Sarah Nagy, RN – 615.343.6238
Tami Neal, RN – 615.260.1330
Brenda White, RN – 615.936.2458

---

**Interventional/Surgery Studies**

**Cardiac Catheterization**

**BNP Study**
To measure levels of NPs in the cardiac chambers/vessels
PI-Monahan
SC – Blair-Anton

**PREDICT**
Female, Non-DM-no prior hx of CAD
One time blood draw to detect genetic factors
PI-McPherson
SC – Crum/Clark

**GRAVITAS**
Gauging Responsiveness with a Verify Now Assay - Impact on Thrombosis and Safety; 6-Month
Single or double dose Plavix with a point of care device used to detect platelet inhibition
PI-Robbin
SC – Clark/Crum

**CAD**

**MI/ACS**

**Non-Q-Wave MI**

**DAPT Registries**
Dual anti-platelet therapy post-stent
PI-McPherson
SC – LaFontaine/Clark

**TRACER**
Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a thrombin inhibitor vs standard of care in subjects with ACS
PI – Cleator
SC – Gordon/Blair-Anton

**1st Time MI/Non-ST EF 20-45%, no CABG Hx**

**PROCHYMAL**
Allogeneic cultured adult human mesenchymal stem cells to improve LV dysfunction after MI
PI – Zhao
SC – Blair-Anton/Crum

**1st ST Elevation MI EF ≤45%**

**TIME (3-7 days) or Late-Time (14 days)**
Autologous bone marrow stem cells post MI to prevent/improve LV function
PI – Zhao
SC – Francescon/Bowman

**RED CABG**
AcaDesine vs. placebo to prevent reperfusion ischemia injury during cardioplegia
PI – McPherson
SC – Gordon/Blair-Anton

**Cardiac Surgery**

**REDCABG**
AcaDesine vs. placebo to prevent reperfusion ischemia injury during cardioplegia
PI – McPherson
SC – Gordon/Blair-Anton

---

**DETERMINE**
ICD vs. Usual Care for post MI; EF >35% (>10% scar by MRI)
PI – Saavedra
SC – Nagy/Neal

---

Flow chart
If you have a patient who may qualify, please contact Study Coordinator (SC) Contact Numbers:
Lynn Blair-Anton, RN – 615.484.3657
Rachel Criswell, MS – 615.936.7191
Mary Gordon, RN – 615.936.8377
Beth Meador, NP – 615.936.1641
Sarah Nagy, RN – 615.343.6238
Tami Neal, RN – 615.260.1330

**General Cardiology**

**VHVI Main Heart Registry**
- PI – McPherson
- SC - Criswell

**Patent Foramen Ovale**
- Stroke unknown cause

**Hypercholesterolemia**
- **ISIS-Extension Study**
  - An open-label extension study to assess the long-term safety and efficacy of phosphorothioate oligonucleotide in subjects with familial or severe hypercholesterolemia
  - PI – Linton
  - SC – Meador

- **RESPECT Study**
  - Randomized evaluation of recurrent stroke comparing PFO closure to established standard of care treatment
  - PI – Piana
  - SC – Gordon/Blair-Anton

- **Hypertension** (Systolic bp ≥ 140 and/or diastolic bp of ≥ 90, or on anti-hypertensives)
  - **ALISKIREN**
    - The effects of renin inhibition on fibrinolytic balance and endothelial function
    - PI – Muldowney
    - SC – Neal/Nagy

- **Initiating Warfarin Therapy**
  - **COAG Study**
    - A randomized, multicenter, double-blind clinical trial to evaluate efficacy in the use of clinical plus genetic information to guide warfarin therapy initiation and improve anticoagulation control for patients
    - PI – Muldowney
    - SC – Neal/Nagy